| Brand | Abnova |
| Product type | Primary antibodies |
| Reactivity | Human |
| Host species | Goat |
| Applications | ELISA,WB-Ti,IHC-P |
| Brand: | Abnova |
| Reference: | PAB7023 |
| Product name: | AKR1C4 polyclonal antibody |
| Product description: | Goat polyclonal antibody raised against synthetic peptide of AKR1C4. |
| Gene id: | 1109 |
| Gene name: | AKR1C4 |
| Gene alias: | 3-alpha-HSD|C11|CDR|CHDR|DD4|HAKRA|MGC22581 |
| Gene description: | aldo-keto reductase family 1, member C4 (chlordecone reductase; 3-alpha hydroxysteroid dehydrogenase, type I; dihydrodiol dehydrogenase 4) |
| Immunogen: | A synthetic peptide corresponding to human AKR1C4. |
| Immunogen sequence/protein sequence: | DPKYQRVELNDGH-C |
| Protein accession: | NP_001809.2 |
| Form: | Liquid |
| Concentration: | 0.5 mg/mL |
| Recommend dilutions: | ELISA (1:4000) Western blot (0.1-0.3 ug/mL) Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) (2-4 ug/mL) The optimal working dilution should be determined by the end user. |
| Storage buffer: | In Tris saline, pH 7.3 (0.5% BSA, 0.02% sodium azide) |
| Storage instruction: | Store at -20°C. Aliquot to avoid repeated freezing and thawing. |
| Quality control testing: | Antibody Reactive Against Synthetic Peptide. |
| Note: | This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
| Product type: | Primary antibodies |
| Host species: | Goat |
| Antigen species / target species: | Human |
| Specificity: | This antibody may cross-react with AKR1C1. |
| Reactivity: | Human |
| Application image: | ![]() |
| Application image note: | AKR1C4 polyclonal antibody (Cat # PAB7023) (0.1 ug/mL) staining of human liver lysate (35 ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence. |
| Applications: | ELISA,WB-Ti,IHC-P |
| Shipping condition: | Dry Ice |
| Publications: | Polymorphisms in genes involved in estrogen and progesterone metabolism and mammographic density changes in women randomized to postmenopausal hormone therapy: results from a pilot study.Lord SJ, Mack WJ, Van Den Berg D, Pike MC, Ingles SA, Haiman CA, Wang W, Parisky YR, Hodis HN, Ursin G. Breast Cancer Res. 2005;7(3):R336-44. Epub 2005 Feb 23. |